Feb 16 2024 This Week in Cardiology

This Week in Cardiology

An update in trial interpretation, CI, and P-values; percutaneous tricuspid Interventions; and news on HDL and humility in Medicine are the topics John Mandrola, MD, covers in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Evidence of Absence Is not Absence of Evidence

Feb 09, 2024 This Week in Cardiology Podcast

https://www.medscape.com/viewarticle/1000101

• ARCADIA Trial https://jamanetwork.com/journals/jama/fullarticle/2814933
• FOURIER Trial https://www.nejm.org/doi/full/10.1056/nejmoa1615664
• Sample Size Calculator https://clincalc.com/stats/samplesize.aspx

II. Tricuspid Valve Interventions

FDA OKs First Transcatheter Tricuspid Valve Replacement

https://www.medscape.com/viewarticle/fda-oks-first-transcatheter-tricuspid-valve-replacement-2024a10002dq

FDA Panel in Favor of TriClip for Tricuspid Regurgitation

https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037n

• Cardiothoracic Surgical Trials Network Study https://www.nejm.org/doi/full/10.1056/NEJMoa2115961
• TRILUMINATE https://www.nejm.org/doi/full/10.1056/NEJMoa2300525
• KAUL Tweet on ATTR Cardiomyopathy https://twitter.com/kaulcsmc/status/1753552603534016622?s=20
• APOLLO B trial https://www.nejm.org/doi/full/10.1056/NEJMoa2300757
• Al-Lamee Tweet on Sham Controls https://x.com/rallamee/status/1758236588570562736

III. HDL Cholesterol

• Rationale paper — AEGIS https://doi.org/10.1016/j.ahj.2020.10.052
• Press Release AEGIS II https://www.prnewswire.com/news-releases/csl-announces-top-line-results-from-the-phase-3-aegis-ii-trial-evaluating-the-efficacy-and-safety-of-csl112-apolipoprotein-a-i-human-302059156.html

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [e-mail]